# KymaThera

Source: https://onco.cc/companies/kymathera/  
OnCo record `kymathera` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KymaThera is developing K-1728, a pill that blocks the faulty forms of the PI3K-alpha enzyme found in many hormone receptor-positive breast cancers while largely sparing the normal enzyme. It expected to start its first human trial in late 2026.

## Summary

KymaThera, based in San Diego, develops small-molecule precision therapeutics. Its lead, K-1728, is an oral pan-mutant-selective PI3Kα inhibitor designed to inhibit both kinase-domain and helical-domain PIK3CA mutations while largely sparing wild-type PI3Kα. It is being developed for HR-positive, HER2-negative breast cancer, alone and in combination, and as monotherapy for PI3Kα-driven vascular malformations. In October 2026 the company closed an USD 80 million Series B led by Alta Partners with Venrock, Foresite Capital and J. Wood Capital, bringing total capital raised to more than USD 100 million; it expected to dose the first patient in a phase 1 study in the fourth quarter of 2026. Rob Kania is chief executive.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: San Diego, CA
- Type: biotech
- Website: https://kymathera.com/

## Notes

- Founding year and headquarters address not stated on the company website; San Diego is the dateline of the Series B release. The 2024 Series A is the earliest financing found; whether an earlier seed round existed was not established. No human data had been reported at the time of writing.

## Sources

- Official website: https://kymathera.com/
- Series B release, October 2026: https://www.prnewswire.com/news-releases/kymathera-announces-80-million-series-b-financing-to-advance-k-1728-a-next-generation-pan-mutant-selective-pi3k-inhibitor-for-cancer-and-vascular-malformations-302899716.html

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PI3K, AKT and mTOR inhibitors](https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- companies: [Foresite Capital](https://onco.cc/companies/foresite-capital/), [Venrock](https://onco.cc/companies/venrock/)

---
JSON: https://onco.cc/api/v1/entities/kymathera.json